(Press-News.org) Aug. 6, 2012
ROCHESTER, Minn. -- Many people have probably heard of off-label drug use, but they may not know when that applies to prescriptions they are taking, a Mayo Clinic analysis found. Off-label drug use occurs when a physician prescribes medication to treat a condition before that use has been approved by the Food and Drug Administration. In a newly published article in Mayo Clinic Proceedings, researchers pose and answer 10 questions about off-label drug use.
"Since the Food and Drug Administration does not regulate the practice of medicine, off-label drug use has become very common," says lead author Christopher Wittich, M.D., internal medicine physician at Mayo Clinic. "Health care providers and patients should educate themselves about off-label drugs to weigh the risks and benefits before a physician prescribes one or a patient takes one."
Some highlights from the article:
Off-label drug use is common. Within a group of commonly used medications, roughly 1 in 5 prescriptions were for an off-label use, a 2006 report found. Another study found that about 79 percent of children discharged from pediatric hospitals were taking at least one off-label medication.
Patients may not know when drugs they have been prescribed are being used off-label. No court decision has required that physicians must disclose, through informed consent, the off-label use of a drug, the authors say. The FDA makes clear that it doesn't regulate the practice of medicine and that the federal Food, Drug, and Cosmetic Act of 1938 doesn't make physicians liable for off-label drug use, they note.
Off-label drug use can become the predominant treatment for a condition. For example, some antidepressants are not approved by the FDA as a treatment for neuropathic pain, yet some drugs in this class are considered a first-line treatment option.
Examples of widely practiced off-label drug use include morphine, used extensively to treat pain in hospitalized pediatric patients. Many inhaled bronchodilators, antimicrobials, anticonvulsants, and proton pump inhibitors also are used in children without formal FDA approval.
Obtaining new FDA approval for a medication can be costly and time-consuming. To add additional indications for an already approved medication requires a supplemental drug application; if eventually approved, revenue from it may not offset the expense and effort for obtaining approval.
Generic medications may not have the requisite funding resources needed to pursue FDA-approval studies. For these financial reasons, drug proprietors may never seek FDA approval for a new drug indication.
Pharmaceutical manufacturers are not allowed to promote off-label uses of medications. However, they can respond to unsolicited questions from health care providers and distribute peer-reviewed publications about off-label use. Just this year, GlaxoSmithKline agreed to pay a record $3 billion to settle a Justice Department case involving alleged off-label drug use marketing, and Merck Sharp & Dohme was fined $322 million over its alleged promotion of the painkiller Vioxx for an off-label use.
###
To interview Dr. Wittich about off-label drug use, contact Nick Hanson at 507-284-5005 or newsbureau@mayo.edu.
About Mayo Clinic Proceedings
The flagship journal of Mayo and arguably one of the premier peer-reviewed clinical journals in general medicine, Mayo Clinic Proceedings is among the most widely read and highly cited scientific publications for physicians, with a circulation of approximately 124,000. While the journal is sponsored by Mayo Clinic, it welcomes submissions from authors worldwide, publishing articles that focus on clinical medicine and support the professional and educational needs of its readers.
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.mayoclinic.org/about/ and http://www.mayoclinic.org/news/.
Nick Hanson
507-284-5005 (days)
507-284-2511 (evenings)
Email: newsbureau@mayo.edu
JOURNALISTS: For multimedia resources including video interviews with study authors, visit the Mayo Clinic News Network.
Off-label drug use common, but patients may not know they're taking them, Mayo finds
2012-08-06
ELSE PRESS RELEASES FROM THIS DATE:
Airborne technology helps manage elephants
2012-08-06
Washington, D.C. – For years, scientists have debated how big a role elephants play in toppling trees in South African savannas. Tree loss is a natural process, but it is increasing in some regions, with cascading effects on the habitat for many other species. Using high resolution 3-D mapping, Carnegie scientists have for the first time quantitatively determined tree losses across savannas of Kruger National Park. They found that elephants are the primary agents—their browsing habits knock trees over at a rate averaging 6 times higher than in areas inaccessible to them. ...
Empa X-ray expert 'decodes' diesel soot
2012-08-06
Soot particles are dangerous – there is nothing new in this knowledge. But what is it that makes fine particulates dangerous? Is it only diesel soot from vehicle engines? Does the danger also come from wood-burning stoves in holiday chalets? Or even from grease-laden fryer fumes from the restaurant around the corner? For a long time, these questions have been a hard nut for science to crack. Indeed, fine soot particles were collected in filters and their chemical components were analysed. Yet the question remained: what precisely is the source of the danger? Is it the soot ...
Press freedom leads to happiness, environmental quality, MU study finds
2012-08-06
COLUMBIA, Mo. — Freedom of the press is viewed by many as a cornerstone of democracy. But can it actually help improve people's lives and make them happy? Researchers at the University of Missouri have found that citizens of countries with press freedom tend to be much happier than citizens of countries without free presses. Edson Tandoc, Jr., a doctoral student in the MU School of Journalism, says that press freedom directly predicts life satisfaction across the world.
"We already know that having reliable, objective news sources can benefit democracy, but in this study, ...
Adalimumab is a promising therapy for children with Crohn's disease
2012-08-06
Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.
Steroids are commonly used in Crohn's disease, but can stunt growth and delay puberty. Incidence of this disease, which causes intestinal inflammation, is on the rise in children.
This study is the largest double-blind study of an anti-TNF agent in children with Crohn's disease. It found that more than 80 ...
'Green biased' yellow fever swept through Irish Immigrants in 19th century US
2012-08-06
New research by University of Warwick historian Dr Tim Lockley has found why yellow fever had a green bias in 19th century fever outbreaks in the southern states of the US. Almost half of the 650 people killed by yellow fever in Savannah Georgia in 1854 were Irish immigrants.
Dr Tim Lockley's study is based on four sources: the burial records of Laurel Grove cemetery; the records of the city's Catholic cemetery; the minutes of Savannah's Board of Health; and published lists of the dead in the Savannah Morning News. These sources yielded the names of 650 people who died ...
Infants of overweight mothers grow more slowly
2012-08-06
Pregnant women who are overweight or obese can encounter a host of health complications. The added weight also appears to affect how their children grow and develop, at least initially.
In a new study published in the Journal of Pediatrics, a team led by a University of Iowa researcher compared the weight and height of babies born to overweight and obese mothers with those born to normal-weight mothers.
Contrary to expectations, babies of overweight/obese mothers gained less weight and grew less in length than babies of normal-weight women from just after birth to ...
Brain's stem cells 'eavesdrop' to find out when to act
2012-08-06
Working with mice, Johns Hopkins researchers say they have figured out how stem cells found in a part of the brain responsible for learning, memory and mood regulation decide to remain dormant or create new brain cells. Apparently, the stem cells "listen in" on the chemical communication among nearby neurons to get an idea about what is stressing the system and when they need to act.
The researchers say understanding this process of chemical signaling may shed light on how the brain reacts to its environment and how current antidepressants work, because in animals these ...
Creatine aids women in outmuscling major depression
2012-08-06
(SALT LAKE CITY)—Women battling stubborn major depression may have a surprising new ally in their fight—the muscle-building dietary supplement creatine.
In a new proof-of-concept study, researchers from three South Korean universities and the University of Utah report that women with major depressive disorder (MDD) who augmented their daily antidepressant with 5 grams of creatine responded twice as fast and experienced remission of the illness at twice the rate of women who took the antidepressant alone. The study, published Aug. 3, 2012, in the American Journal of Psychiatry ...
Those who are covered, recover
2012-08-06
Insurance status is a better predictor of survival after a serious cardiac event than race, and may help explain racial disparities in health outcomes for cardiovascular disease. A new study by Derek Ng, from the Johns Hopkins Bloomberg School of Public Health in the US, and his team shows that race is not linked to an increased risk of death but being underinsured is a strong predictor of death among those admitted into hospital with a serious cardiac event. Their work¹ appears online in the Journal of General Internal Medicine², published by Springer.
African Americans ...
Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
2012-08-06
A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG. The Phase II, open-label, multicenter study in patients with advanced neuroendocrine tumors (NET) whose symptoms were no longer responsive to octreotide LAR therapy found that the drug was effective and well tolerated in controlling patient symptoms.
The study results are reported in a recent issue of Endocrine-Related Cancer, a publication of ...